Furthermore, Schmutz et al., utilizing DNA methylation patterns, identified 1755 specific DMRs, including genes like WNT10A and GATA-3, to predict treatment response in AML patients undergoing AZA-containing induction therapy [31]. This evidence concerns the gene GATA3 and acute myeloid leukemia.